Microbix Biosystems, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Microbix Biosystems, Inc.
Zydus gets rights to re-launch, manufacture Microbix's urokinase
The Canadian firm, Microbix Biosystems, has licensed all rights and expertise concerning its thrombolytic drug, Kinlytic (urokinase), to Zydus Cadila under a milestone-cum-royalty-based pact that aims to reintroduce the product in North America.
Deals Shaping The Medical Industry (03/2012)
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
Zydus to back Microbix's urokinase relaunch plans in North America
The Canadian firm, Microbix Biosystems, will receive financial backing and regulatory support from Zydus Cadila of India for the proposed relaunch of the thrombolytic drug, urokinase, in the North America.
$250 million Canada-China flu vaccine JV stalls after spat over deal renegotiation
The future looks uncertain for a joint venture that had been limbering up to build Asia's largest influenza vaccine facility in Hunan province, China. One of the joint venture partners, Canadian firm Microbix Biosystems, says it has suspended all activity and returned finances raised from private investors in January, after running into an impasse in negotiations with its Chinese partner over amendments to the deal they originally signed in 2008.
- In Vitro Diagnostics
- Medical Devices
- Drug Delivery
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.